TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03310463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514SUL
Description: Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514SUL
Description: Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514SUL
Description: Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514SUL
Description: Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514SUL
Description: Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
Study: NCT00818025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pocket PATH (Personal Assistant for Tracking Health)
Description: Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
Study: NCT01113515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study: NCT03656133

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy fractionation
Description: Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)
Study: NCT04590235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m\^2. After a washout period of 2 days, oral selumetinib 25 mg/m\^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first.~10 mg and 25 mg capsules strengths available.
Study: NCT03733587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: GX-I7 25mg/ml/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500mg/vial
Study: NCT03796494

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Straight abutment
Description: This is the classic abutment, straight and anti-rotational for dental implants which have been tested before

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slim abutment
Description: This is the new concept of the prostheses abutment, slim and anti-rotational to improve the width of biologic space
Study: NCT04493437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
Study: NCT00200096

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: placebo acupuncture
Description: During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure.
Study: NCT00662220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 25-29 mg/kg/day
Study: NCT03519451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Given KickAsh smartphone mobile application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Given Breathe2Relax smartphone mobile application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00462943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.
Study: NCT02484365

Intervention type: OTHER
Intervention: No treatment
Description: Attach adhesive probe on thumb or index finger
Study: NCT01542619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVIIa-FP
Description: Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% normal saline)
Description: Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
Study: NCT00662220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 12-15 mg/kg/day
Study: NCT05666622

Intervention type: OTHER
Group type: OTHER
Intervention: Only routine non-surgical periodontal treatment was applied to the patients.
Description: The study included 70 systemically healthy individuals, as a test group of 35 patients with Stage 3, Grade A periodontitis and a control group of 35 individuals with no periodontal disease. Blood samples were taken for the examination of DNI, white blood cells (WBC), immature granulocytes (IG), procalcitonin, C-reactive protein (CRP), lymphocyte count and neutrophil count. For the patients with periodontitis, blood sample assays were repeated 3 months after non-surgical periodontal treatment
Study: NCT03042793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 peptide vaccine
Description: PD-L1 peptide given subcutaneously with Montanide ISA-51
Study: NCT02372903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin
Description: Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
Study: NCT03702205

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine supplementation
Description: Group taking oral betaine supplementation
Study: NCT02758262

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive brain stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Noninvasive brain stimulation
Study: NCT02942056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: Cinnamon tablets to treat type 2 DM
Study: NCT03702205

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine supplementation
Description: Group taking oral betaine supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Description: Group taking oral supplementation with placebo (starch) in a similar capsule form.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Description: Group taking oral supplementation with placebo (starch) in a similar capsule form.
Study: NCT02942056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01151033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent implantation
Description: ProNOVA XR Drug Eluting Stent implantation
Study: NCT01110174

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HD PET/CT
Description: imaging
Study: NCT01450930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone intramuscular first
Description: Hydrocortisone intramuscular first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone subcutaneously first
Description: Hydrocortisone subcutaneously first
Study: NCT05387720

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual diaphragmatic facilitation (PNF) technique
Description: Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trigger sensitivity adjustment on mechanical ventilation
Description: The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique
Description: Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
Study: NCT03107663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ⁸⁹Zr-Df-IAB22M2C Infusion
Description: A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
Study: NCT02121782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: GC3110A, 0.5ml, intramuscular, a single dosing at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: GC3110A, 0.5ml, intramuscular, a single dosing at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine
Description: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
Study: NCT01737502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02883166

Intervention type: DRUG
Group type: OTHER
Intervention: abiraterone
Description: integested with a continental breakfast

Intervention type: DRUG
Group type: OTHER
Intervention: abiraterone
Description: integested with a continental breakfast
Study: NCT04107779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS
Description: JUUL 5%, ENDS for 6-days in confinement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS
Description: JUUL 3%, ENDS for 6-days in confinement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS
Description: JUUL 5%, ENDS for 6-days in confinement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS
Description: JUUL 3%, ENDS for 6-days in confinement
Study: NCT01644422

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection

Intervention type: OTHER
Group type: OTHER
Intervention: Standard hair follicle transplant
Description: Control arm subject will receive Standard hair follicle transplant
Study: NCT00725764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (foretinib)
Description: Multitargeted tyrosine kinase inhibitor
Study: NCT04031560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative treatment
Description: The experimental group (62 patients) will take part on the integrative group program consisting of 12-sessions, 90 minutes each, once a week (4 focused on psychoeducation, 1 directed to the family relatives, 3 on mindfulness and 4 on functional remediation)
Study: NCT02199379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
Study: NCT01928615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab - intravenous solution
Description: Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab - intravenous solution
Description: Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab - subcutaneous solution
Description: Trastuzumab was supplied as a solution for subcutaneous injection.
Study: NCT04095923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media game
Description: Participants will engage in weekly challenges that require them to take photographs of interesting things they discover during their walks. They will post and discuss these photographs with other participants on a private social media page. They will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
Study: NCT04250207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: Placebo solution drops for K-321
Study: NCT04278924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-079 placebo-matching SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-079 placebo-matching SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 SC injection.
Study: NCT04095923

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard self-regulation
Description: Participants will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
Study: NCT03115346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Decision aid for repair type for aortic abdominal aneurysms
Study: NCT02600156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal laser ablation of the prostate
Description: MR guided laser ablation of the focal prostatic lesion which has been identified by MRI and biopsy prior to ablation.
Study: NCT04474600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The induction and maintenance of anesthesia was performed by total intravenous anesthesia using propofol. In both groups, remifentanil is continuously infused throughout the surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: The induction and maintenance of anesthesia was performed by inhalation anesthesia using desflurane. In both groups, remifentanil is continuously infused throughout the surgery.
Study: NCT03861273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06838435/ fidanacogene elaparvovec
Description: Gene Therapy
Study: NCT03788291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100 mg by mouth twice a day starting on day 8 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.
Study: NCT04217421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol powder for solution for infusion (PFI) 20 mg/kg body weight per administration will be administered early postnatally (within 45 minutes and 12 hours after the first dose), preoperatively (12 hours before surgery), intraoperatively (during surgery) and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Allopurinol PFI will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Mannitol powder for solution (PFI) placebo will be administered early postnatally (within 45 minutes and 12 hours after birth), preoperatively (12 hours before surgery), intraoperatively (during surgery), and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Mannitol PFI-placebo will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
Study: NCT02768805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg/strain of Quadrivalent VLP Vaccine
Description: Single dose of non-adjuvanted Quadrivalent VLP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 µg/strain of Quadrivalent VLP Vaccine
Description: Single dose of non-adjuvanted Quadrivalent VLP Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 15 µg/strain of the licensed quadrivalent vaccine
Description: Single dose of the licensed quadrivalent vaccine
Study: NCT01021644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise-training
Description: 3 times per week for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stretch exercise
Description: 3 times per week for 6 months
Study: NCT05541419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal
Description: The patient performed a lavage once daily with 2mg dilute budesonide. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Composed of 1% glycerin diluted in water. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
Study: NCT01061905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie information
Description: Posting of Calorie information for sugar-sweetened and zero-calorie beverages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Equivalent only
Description: Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie & Exercise equivalent information
Description: Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.